{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:13:13Z","timestamp":1789701193321,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00280-017-3310-0","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T10:07:17Z","timestamp":1494583637000},"page":"1141-1149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed\/refractory multiple myeloma: a phase 2 study"],"prefix":"10.1007","volume":"79","author":[{"given":"Yun","family":"Leng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naibai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-9280","authenticated-orcid":false,"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"issue":"4","key":"3310_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren O, Iskander K (2017) Modern multiple myeloma\u00a0therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281(4):365\u2013382. doi: 10.1111\/joim.12590","journal-title":"J Intern Med"},{"issue":"6","key":"3310_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Landgren O (2016) A look backward and forward in the regulatory and treatment history of\u00a0multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol 43(6):682\u2013689. doi: 10.1053\/j.seminoncol.2016.10.008","journal-title":"Semin Oncol"},{"key":"3310_CR3","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/j.1745-7254.2005.00206.x","volume":"26","author":"F Fang","year":"2005","unstructured":"Fang F, Wang AP, Yang SF (2005) Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Phamacologica Sinica 26:1373\u20131381. doi: 10.1111\/j.1745-7254.2005.00206.x","journal-title":"Acta Phamacologica Sinica"},{"key":"3310_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.exphem.2015.10.004","volume":"44","author":"H Zhou","year":"2016","unstructured":"Zhou H, Li J, Jian Y et al (2016) Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Exp Hematol 44:125\u2013131. doi: 10.1016\/j.exphem.2015.10.004","journal-title":"Exp Hematol"},{"key":"3310_CR5","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2147\/OTT.S73731","volume":"8","author":"D Yan","year":"2015","unstructured":"Yan D, Ge Y, Deng H et al (2015) Gefitinib\u00a0upregulates\u00a0death\u00a0receptor\u00a05\u00a0expression to mediate rmhTRAIL-induced apoptosis in\u00a0Gefitinib-sensitive NSCLC cell line. Onco Targets Ther 8:1603\u20131610. doi: 10.2147\/OTT.S73731","journal-title":"Onco Targets Ther"},{"key":"3310_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","volume":"299","author":"SK Kelley","year":"2001","unstructured":"Kelley SK, Harris LA, Xie D et al (2001) Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31\u201338","journal-title":"J Pharmacol Exp Ther"},{"key":"3310_CR7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood.V120.21.1857.1857","volume":"120","author":"WM Chen","year":"2012","unstructured":"Chen WM, Qiu LG, Hou J et al (2012) Phase Ib study of recombinant circularly permuted TRAIL (CPT) in relapsed or refractory multiple myeloma patients. Blood 120:1857 (ASH annual meeting abstracts)","journal-title":"Blood"},{"key":"3310_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40880-016-0140-0","volume":"35","author":"Y Leng","year":"2016","unstructured":"Leng Y, Qiu L, Hou J et al (2016) Phase\u00a0II\u00a0open-label\u00a0study\u00a0of\u00a0recombinant\u00a0circularly\u00a0permuted\u00a0TRAIL\u00a0as a\u00a0single-agent\u00a0treatment for relapsed\u00a0or\u00a0refractory\u00a0multiple myeloma. Chin J Cancer 35:86. doi: 10.1186\/s40880-016-0140-0","journal-title":"Chin J Cancer"},{"key":"3310_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ajh.23822","volume":"89","author":"C Geng","year":"2014","unstructured":"Geng C, Hou J, Zhao Y et al (2014) A multicenter, open-label phase II study of recombinant\u00a0CPT\u00a0(circularly permuted TRAIL) plus thalidomide in patients with relapsed and refractory\u00a0multiple myeloma. Am J Hematol 89:1037\u20131042. doi: 10.1002\/ajh.23822","journal-title":"Am J Hematol"},{"key":"3310_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2013.0004","volume":"11","author":"KC Anderson","year":"2013","unstructured":"Anderson KC, Alsina M, Bensinger W et al (2013) Multiple myeloma, version 1, 2013. J Natl Compr Canc Netw 11:11\u201317","journal-title":"J Natl Compr Canc Netw"},{"key":"3310_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3760\/cma.j.issn.0578-1426.2016.02.004","volume":"55","author":"W Chen","year":"2016","unstructured":"Chen W (2016) The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision): interpretation of the treatment of relapsing and refractory multiple myeloma. Zhonghua Nei Ke Za Zhi 55:93\u201394. doi: 10.3760\/cma.j.issn.0578-1426.2016.02.004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"3310_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102:1115\u20131123. doi: 10.1046\/j.1365-2141.1998.00930.x","journal-title":"Br J Haematol"},{"key":"3310_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, International\u00a0Myeloma\u00a0Working Group et al (2006) International\u00a0uniform\u00a0response\u00a0criteria\u00a0for\u00a0multiple myeloma. Leukemia 20:1467\u20131473. doi: 10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"3310_CR14","first-page":"399","volume":"86","author":"A Palumbo","year":"2001","unstructured":"Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399\u2013403","journal-title":"Haematologica"},{"key":"3310_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991\u2013995. doi: 10.1023\/A:1011132808904","journal-title":"Ann Oncol"},{"key":"3310_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","volume":"121","author":"A Anagnostopoulos","year":"2003","unstructured":"Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768\u2013771. doi: 10.1046\/j.1365-2141.2003.04345.x","journal-title":"Br J Haematol"},{"key":"3310_CR17","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood.V124.21.3478.3478","volume":"124","author":"WM Chen","year":"2014","unstructured":"Chen WM, Wei P, Yang SF et al (2014) Transiently elevated AST\/LDH are associated with clinical response to recombinant circularly permuted TRAIL (CPT) plus thalidomide in patients with relapsed and\/or refractory multiple myeloma. Blood 124:3478 (ASH annual meeting abstracts)","journal-title":"Blood"},{"key":"3310_CR18","first-page":"369","volume":"99","author":"P Wei","year":"2014","unstructured":"Wei P, Yang S, Zheng X et al (2014) Transient elevation of AST or LDH as an early pharmacodynamic biomarker of recombinant circularly permuted trail (CPT) in treating patients with relapsed or refractory multiple myeloma. Haematologica 99:369 (19th congress of EHA Abstracts, Abstract P974)","journal-title":"Haematologica"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3310-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3310-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3310-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:39:43Z","timestamp":1750253983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3310-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3310-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]}}}